Features of the course and outcomes of COVID-19 in patients with axial spondyloarthritis
https://doi.org/10.47360/1995-4484-2022-267-270
Abstract
The 2019 coronavirus disease pandemic (COVID-19) is particularly challenging not only for doctors, but also for patients with inflammatory diseases, including spondyloarthritis. Although a large number of studies have been conducted over the past 2 years on the effect of COVID-19 on patients with rheumatic diseases, however, the conclusions from them are not always unambiguous. Given the growing number of cases of COVID-19 infection worldwide, there is a need to study the impact of individual diseases on its outcomes. The results of the study of COVID-19 in spondyloarthritis are limited to isolated reports of cases of the disease. Moreover, there is practically no literature devoted to the outcomes of COVID-19 exclusively in patients with axial spondyloarthritis. However, over the past few months, two large studies have been publishe d, in total, analyzing the outcomes of infection with SARS-CoV-2 in more than 14,000 patients with spondyloarthritis. The article discusses the results of these studies, the result of which is the conclusion that the presented data should convince both patients and doctors that axial spondyloarthritis and the therapy carried out for its treatment does not increase the risk of infection and does not aggravate the outcomes of COVID-19.
About the Author
Sh. F. Erdes
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
References
1. Schreiber K, Hendricks O. First data on COVID-19 morbidity and mortality in patients with rheumatic disease from South Korea. Lancet Rheumatol. 2021;3(10):e673-e675. doi: 10.1016/ S2665-9913(21)00213-7
2. Wang F, Ma Y, Xu S, Liu H, Chen Y, Yang H, et al. Prevalence and risk of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis. Clin Rheumatol. 2022;41(7):2213-2223. doi: 10.1007/s10067-022-06087-1
3. Nasonov EL, Belov BS, Lila AM, Aronova ES, Gridneva GI, Kudryavtseva AV, et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2021;59(6):666-675 (In Russ.). doi: 10.47360/1995-4484-2021-666-675
4. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871
5. Jorge A, D’Silva KM, Cohen A, Wallace ZS, McCormick N, Zhang Y, et al. Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: A cohort study. Lancet Rheu matol. 2021;3(2):e131-e137. doi: 10.1016/S2665-9913(20)30422-7
6. D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-920. doi: 10.1002/art.41619
7. Nørgård BM, Zegers FD, Nielsen J, Kjeldsen J. Post COVID-19 hospitalizations in patients with chronic inflammatory diseases – A nationwide cohort study. J Autoimmun. 2021;125:102739. doi: 10.1016/j.jaut.2021.102739
8. El Hasbani G, Jawad A, Uthman I. Axial and peripheral spondyloarthritis triggered by SARS-CoV-2 infection: A report of two cases. Reumatismo. 2021;73(1):59-63. doi: 10.4081/reumatismo.2021.1374
9. Saikali W, Gharib S. The first non-radiographic axial spondyloarthrits with COVID-19. Immun Inflamm Dis. 2021;9(3):628-631. doi: 10.1002/iid3.448
10. Rumiantceva DG, Urumova MM, Erdes SF. New coronavirus infection COVID-19 as a trigger for the development of symptoms of ankylosing spondylitis. Case report. Terapevticheskii arkhiv. 2021;93(5):609- 612 (In Russ.). doi: 10.26442/00403660.2021.05.200793
11. Rosenbaum JT, Hamilton H, Choi D, Weisman MH, Reveille JD, Winthrop KL. Biologics, spondylitis and COVID-19. Ann Rheum Dis. 2020;79(12):1663-1665. doi: 10.1136/annrheumdis-2020-217941
12. Rosenbaum JT, Weisman MH, Hamilton H, Shafer C, Aslanyan E, Howard RA, et al. The interplay between COVID-19 and spondyloarthritis or its treatment. J Rheumatol. 2022;49(2): 225-229. doi: 10.3899/jrheum.210742
13. Raiker R, Pakhchanian H, Kavadichanda C, Gupta L, Kardeş S, Ahmed S. Axial spondyloarthritis may protect against poor outcomes in COVID-19: Propensity score matched analysis of 9766 patients from a nationwide multi-centric research network. Clin Rheumatol. 2022;41(3):721-730. doi: 10.1007/s10067-021-05979-y
14. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498
15. Baslılar S, Pehlivan O. Evaluation of factors affecting the frequency and clinical course of COVID-19 in patients using anti-TNF-alpha agents. Rev Assoc Med Bras (1992). 2021;67(9):1286-1292. doi: 10.1590/1806-9282.20210568
16. Wong AY, MacKenna B, Morton CE, Schultze A, Walker AJ, Bhaskaran K, et al.; OpenSAFELY Collaborative. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: An OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021;80(7):943-951. doi: 10.1136/annrheumdis-2020-219517
Review
For citations:
Erdes Sh.F. Features of the course and outcomes of COVID-19 in patients with axial spondyloarthritis. Rheumatology Science and Practice. 2022;60(3):267-270. (In Russ.) https://doi.org/10.47360/1995-4484-2022-267-270
Views:
415
Email this article 